Industry.
Nasal Spray and Inhalation Solution, Suspen-
sion, and Spray Drug Products—Chemistry, Manufac-
turing, and Controls Documentation. (2002). Available
at:
http://www.fda.gov/downloads/Drugs/Guidance
ComplianceRegulatoryInformation/Guidances/ucm07
0575.pdf.
8. US Food and Drug Adminstration. Draft Guidance
for Industry. Bioavailability and Bioequivalence Studies
for Nasal Aerosols and Nasal Sprays for Local Action.
(2003). Available at: http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm070111.pdf.
9. European Medicines Agency. Guideline on the Phar-
maceutical Quality of Inhalation and Nasal Products
(2005). Available at: http://www.ema.europa.eu/
docs/en_GB/document_library/Scientific_guideline/2
009/09/WC500003568.pdf.
10.
AAMI/ANSI HE75 (2009), Human Factors Engi-
neering—Design of Medical Devices.
11.
Hearnden, V, et al., New Developments and
Opportunities in Oral Mucosal Drug Delivery for Local
and Systemic Disease. Adv Drug Deliver Rev, 64, 16-
28, 2012.
12. Wikipedia, Subligual administration. Available at:
https://en.wikipedia.org/wiki/Sublingual_administration.
Gerallt Williams is Director of Scientific Affairs at Aptar
Pharma, Prescription Division, Route des Falaises 27100 Le
Vaudreuil Cedex, France, Tel: +33 2 32 63 73 73,
gerallt.williams@aptar.com. Website: www.aptar.com/
pharma.
w ww asia2016 .com/ e n i nl o dd r . w
i l d a e D
2016
6 1 0 2 June 24, : e n
Inhalation JUNE 2016 15
